Lance Miller, PhD
Lance Miller, PhD, specializes in cancer research and functional genomics and uses gene expression profiling to develop diagnostics, therapeutic targets and treatments for cancer. His research can lead to collaborations with pharmaceutical companies and clinicians that improve patient diagnosis, treatment and outcomes.
About Lance Miller
Lance Miller, PhD, completed his doctorate at the University of North Carolina-Chapel Hill in 2001. He studied the molecular biology of breast cancer at the National Cancer Institute, where he first worked with microarray technology and established a DNA microarray core facility for the institute. He later helped develop the Genome Institute of Singapore, part of a multi-billion-dollar project that established a multi-institutional biomedical research program for the government of Singapore, similar to the National Institutes of Health. He was recruited to join the cancer biology department of Wake Forest School of Medicine in 2008.
Lance Miller’s primary research interests center around the use of functional genomics methods to better understand mechanisms of cancer growth and survival. He focuses on tumor-immune system interactions in aggressive forms of breast cancer, including triple negative breast cancers, but he also collaborates in studies involving lung, colon and appendiceal cancers. Through gene expression profiling, he is developing a genetic perspective of cancer that examines the similarities and differences between and within types of cancers in order to better understand the nature of the disease.
Miller seeks to translate his discoveries into technologies that will impact patient care. Using genomic technologies such as next generation sequencing and DNA microarrays, he discovers diagnostic and prognostic markers that help inform patient treatment strategies. As co-director of the Cancer Genomics Core, he helps move this genomic research into the clinical field by determining new directions for research and therapeutics and examines ways to provide clinicians with the information needed to practice precision medicine. His research may also indicate potential therapeutic targets, which could lead to collaborations with pharmaceutical companies and clinicians that will improve patient diagnosis, treatment and outcomes.
The translational aspects of Miller’s research challenge him to advance his understanding of cancer and genomic variations. He believes that cancer genomics requires a multidisciplinary approach in which clinicians, technologists, basic scientists and industries partner to explore the field’s potential. His own research generates possible cancer diagnostic markers and therapeutic targets that can be explored through multidisciplinary cancer research and clinical trial programs at Wake Forest Baptist Medical Center.
Lance Miller, PhD, associate professor of cancer biology at Wake Forest School of Medicine, co-directs the Cancer Genomics Core at the Comprehensive Cancer Center and specializes in:
- Translational research
- Technology and technique development
- Cancer bioinformatics
- Gene expression and mutational profiling
- Breast cancer
- Next generation sequencing
- DNA microarrays